Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness : An Exploratory Study
(2023) In Journal of Palliative Medicine 26(3). p.402-405- Abstract
Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All... (More)
Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All three had worsening illness at the time of the second assessment. There was no apparent relationship between change in testosterone, morphine dose, and change in breathlessness. Conclusions: Substantial declines in testosterone were uncommon and were not apparently related to changes in morphine dose or breathlessness, but they were possibly related with worsening illness.
(Less)
- author
- Ferreira, Diana H. ; Ekstrom, Magnus LU ; Fazekas, Belinda and Currow, David C.
- organization
- publishing date
- 2023-03-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- persistent breathlessness, placebo, randomized controlled trial, safety, sustained-release morphine, testosterone
- in
- Journal of Palliative Medicine
- volume
- 26
- issue
- 3
- pages
- 4 pages
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- pmid:36394475
- scopus:85149415139
- ISSN
- 1096-6218
- DOI
- 10.1089/jpm.2022.0381
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.
- id
- 8fd256a0-1d9f-4432-b36b-8b5014b1cbd5
- date added to LUP
- 2024-01-12 14:25:12
- date last changed
- 2024-04-13 07:51:49
@article{8fd256a0-1d9f-4432-b36b-8b5014b1cbd5, abstract = {{<p>Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All three had worsening illness at the time of the second assessment. There was no apparent relationship between change in testosterone, morphine dose, and change in breathlessness. Conclusions: Substantial declines in testosterone were uncommon and were not apparently related to changes in morphine dose or breathlessness, but they were possibly related with worsening illness.</p>}}, author = {{Ferreira, Diana H. and Ekstrom, Magnus and Fazekas, Belinda and Currow, David C.}}, issn = {{1096-6218}}, keywords = {{persistent breathlessness; placebo; randomized controlled trial; safety; sustained-release morphine; testosterone}}, language = {{eng}}, month = {{03}}, number = {{3}}, pages = {{402--405}}, publisher = {{Mary Ann Liebert, Inc.}}, series = {{Journal of Palliative Medicine}}, title = {{Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness : An Exploratory Study}}, url = {{http://dx.doi.org/10.1089/jpm.2022.0381}}, doi = {{10.1089/jpm.2022.0381}}, volume = {{26}}, year = {{2023}}, }